Clinical trials: insulin glargine
Diabetes Mellitus, Type 2
Glycemic Optimization Treatment Study
To compare the frequency of severe hypoglycemia events for 5 dosing algorithms of Lantus®, each of varying intensity and defined by their end-of -study target for self monitored plasma glucose(SMPG), in patients with Type 2…
- Trial name
- GOT (NCT00552370)
- Testing
- Lantus®
- Volunteers
- 5,062 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Evaluating the Effect of NN1250 at Steady State Conditions in Subjects With Type 1 Diabetes
This trial was conducted in Europe. The aim of this clinical trial was to evaluate the effect on the blood glucose-lowering effect of NN1250 (insulin degludec) in subjects with type 1 diabetes.
- Trial name
- NCT01114542
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 66 people
- Sponsor
- Novo Nordisk A/S
Diabetic Nephropathies
Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy
This is a multi-center, randomized, parallel study to evaluate effect of exenatide on 24h-UAER in patients with diabetic nephropathy. Screening will be made to select eligible participants before intervention.
- Trial name
- NCT02690883
- Testing
- Exenatide, Lispro
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- Nanfang Hospital, Southern Medical University
Diabetes Mellitus, Type 2
Opposing Step-by-step Insulin Reinforcement to Intensified Strategy
Primary objectives : To show the non inferiority in terms of efficacy (HbA1c) of insulin glargine plus metformin combined with 1 to 3 bolus of insulin glulisine introduced progressively (Arm 2) compared with insulin glargine plus…
- Trial name
- OSIRIS (NCT00174642)
- Testing
- Insulin Glargine, Insulin Glulisine, Metformin
- Where
- 18 sites in Belgium, France and 16 more
- Volunteers
- 811 people
- Sponsor
- Sanofi
Diabetes Mellitus, Type 2
A Study to Look at How Safe NNC0268-0965 is in People With Type 2 Diabetes
This study looks at the safety and tolerability of the new medicine NNC0268-0965 (referred to as insulin 965), its concentration in the blood and its effect on the blood sugar for the treatment of diabetes.
- Trial name
- NCT04136067
- Testing
- NNC0268-0965, insulin glargine
- Where
- Germany
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor
The main purpose of this study is to determine the safety and efficacy of orforglipron. Participants will have Type 2 Diabetes (T2D) and have inadequate glycemic control with insulin glargine with or without metformin and/or…
- Trial name
- ACHIEVE-5 (NCT06109311)
- Testing
- Orforglipron
- Where
- 70 sites in United States, Brazil and 4 more
- Volunteers
- 546 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to compare the efficacy and safety of a new basal insulin, insulin peglispro, to insulin glargine in participants with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02106364
- Testing
- Insulin Peglispro, Insulin Glargine
- Where
- 10 sites in United States
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes Mellitus
Improving Glycaemic Control in Malaysian Patients With Type 2 Diabetes Mellitus With Insulin Pump Therapy
The purpose of this study is to evaluate the comparative efficacy of insulin pump therapy versus multiple daily injections in insulin-taking type 2 diabetes mellitus who are sub-optimally controlled with premixed insulin regimen.
- Trial name
- NCT03112538
- Testing
- Insulin Pump, Multiple daily injections of insulin
- Where
- Malaysia
- Volunteers
- 118 people
- Sponsor
- Clinical Research Centre, Malaysia
Gestational Diabetes, Pregnancy Related
Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)
The aim of our study is to compare neonatal and maternal outcomes using different thresholds for the initiation and titration of pharmacotherapy for gestational diabetes (GDM).
- Trial name
- START2 (NCT06419803)
- Testing
- Insulin
- Where
- 2 sites in United States
- Volunteers
- 430 people, healthy volunteers welcome
- Sponsor
- Thomas Jefferson University
Type 2 Diabetes Mellitus
Human Insulin Analogs: Evaluation of Inflammatory mRNA Expression of Macrophages and Endothelial Function of Short-acting Insulin - HERMES Pilot Study
The planned HERMES study is to investigate and compare the effects of Insulin Glulisine, Insulin Aspart and regular human insulin on postprandial nitrotyrosine concentrations and several clinical and laboratory markers of…
- Trial name
- HERMES (NCT01417897)
- Testing
- Insulin glulisine, Insulin aspart, Regular human insulin
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- ikfe-CRO GmbH
Diabetes Mellitus, Type 1, Type 1 Diabetes
Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings
The primary objective of this trial is to determine whether insulin glargine reduces the risk of serious hypoglycemia or improves Time in Range at 6 months when compared against standard of care human insulin (e.g.
- Trial name
- HumAn-1 (NCT05614089)
- Testing
- Insulin Glargine, NPH or premixed 70/30 (human insulin)
- Where
- 3 sites in Bangladesh, Tanzania
- Volunteers
- 400 people
- Sponsor
- Jing Luo
Diabetes, Diabetes Mellitus, Type 1
A Trial Investigating the Effect of NN1250 in Young and Elderly Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of this clinical trial is to investigate the blood glucose lowering effect of NN1250 (insulin degludec) in young and elderly subjects with type 1 diabetes.
- Trial name
- NCT00964418
- Testing
- insulin degludec, insulin glargine
- Where
- Austria
- Volunteers
- 27 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes, Hypoglycemia
Late Night Snack and Insulin Glargine
Twenty patient with Type 1 diabetes, using insulin glargine as basal insulin, participated in a prospective, controlled crossover trial comparing blood glucose profiles over two 24 h periods with and without a late night snack (a…
- Trial name
- NCT02871180
- Testing
- Late night snack, No late night snack
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Diabeteszentrum Bad Lauterberg im Harz
Diabetes Mellitus, Type 2
A Study in Adults With Type 2 Diabetes
The main purpose of this study is to compare the effectiveness and safety of LY2963016 versus Lantus in controlling blood sugar levels in combination with two or more oral diabetes medications.
- Trial name
- ELEMENT 2 (NCT01421459)
- Testing
- LY2963016, Lantus, OAMs
- Where
- 62 sites in United States, Czechia and 10 more
- Volunteers
- 759 people
- Sponsor
- Eli Lilly and Company
Chronic Venous Disease, Varicose Ulcer
Effects of Local Insulin on Varicose Ulcers for Wound Healing
A randomized, split-plot, double-blind, placebo-controlled trial. The varicose ulcer is divided into two (side A and B). Half of the wound's surface is treated locally with insulin (Glargine) applied at an approx depth of 3-4 mm.
- Conditions
- Chronic Venous Disease, Varicose Ulcer, Wound Healing, Insulin
- Trial name
- NCT04310280
- Testing
- Insulin Glargine, Saline
- Where
- Mexico
- Volunteers
- 13 people
- Sponsor
- Hospital Central "Dr. Ignacio Morones Prieto"
Type 2 Diabetes Mellitus
Simplified Insulin Regimen for the Elderly
Basal-bolus insulin therapy, which includes one injection of long acting insulin and three injections of short acting insulin is the most commonly used insulin treatment.
- Trial name
- NCT03660553
- Testing
- Insulin Glargine, Insulin Aspart, Insulin Lispro
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- University of Miami
Type 2 Diabetes Mellitus
Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Basal Insulin With Oral Antidiabetic Therapy
Primary Objective: To compare the efficacy of insulin glargine new formulation and Lantus in terms of change in Glycated Hemoglobin A1c (HbA1c) from baseline to endpoint (scheduled Month 6) in adult participants with type 2…
- Trial name
- EDITION II (NCT01499095)
- Testing
- Lantus (Insulin glargine), HOE901-U300 (new formulation of insulin glargine)
- Where
- 213 sites in United States, Canada and 11 more
- Volunteers
- 811 people
- Sponsor
- Sanofi
Type 1 Diabetes, Dawn Phenomenon
Comparison of Lantus and Neutral Protamine Hagedorn (NPH) Insulin in the Dawn Phenomenon
1. To investigate the effect of insulin glargine (Lantus™) vs NPH insulin regarding glycemic control during the early AM (dawn phenomenon) in individuals with type 1 diabetes. 2.
- Trial name
- DAWN (NCT00694122)
- Testing
- Lantus (glargine)
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Massachusetts General Hospital
Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications
A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes
The GRADE Study is a pragmatic, unmasked clinical trial that will compare commonly used diabetes medications, when combined with metformin, on glycemia-lowering effectiveness and patient-centered outcomes.
- Trial name
- GRADE (NCT01794143)
- Testing
- Sulfonylurea (glimepiride), DPP-4 inhibitor (sitagliptin), GLP-1 receptor agonist (liraglutide)
- Where
- 36 sites in United States
- Volunteers
- 7,850 people
- Sponsor
- GRADE Study Group
Diabetes Mellitus, Type 1 Diabetes
A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus
Type 1 diabetes mellitus (T1DM) is a challenging medical disorder, especially in children and adolescents. In order to prevent the chronic complications of hyperglycemia, the maintenance of near-normal glycemic control must be…
- Trial name
- NCT04157738
- Testing
- Rapid-Acting Insulin, Long acting insulin
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Emory University